Home > Platform Technologies

Cytogel has a portfolio of novel analgesic product candidates and broadly useful polymer and hydrogel drug delivery platform technologies. Cytogel has obtained an exclusive license from Tulane University for the worldwide rights to intellectual property for a family of highly active opioid analgesics relating to and including endomorphin (EM). These agents are the first of an entirely new class of drugs. The Company's drug delivery technologies were acquired from Cornell University, and patent applications have been filed on hydrogels and injectable microspheres. Cytogel will develop products from these platform technologies to the point of demonstrated value and then license these products to other larger companies for the full scientific and clinical development and subsequent commercialization.